Cargando…

Evaluation of S100A12 and Apo-A1 plasma level potency in untreated new relapsing–remitting multiple sclerosis patients and their family members

Multiple sclerosis is an inflammatory disease of the spinal cord and brain. Receptor for advanced glycation end products and Apolipoprotein A1 (Apo-AI) have been recommended to have a pathogenic role in the neuroinflammatory disorder as multiple sclerosis. The purpose of this research was to measure...

Descripción completa

Detalles Bibliográficos
Autores principales:	Samangooei, Mahsa, Farjam, Mojtaba, Etemadifar, Masoud, Taheri, Atefeh, Meshkibaf, Mohammad Hassan, Movahedi, Bahram, Niknam, Zahra, Noroozi, Saam
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8828754/ https://www.ncbi.nlm.nih.gov/pubmed/35140322 http://dx.doi.org/10.1038/s41598-022-06322-4

Ejemplares similares

Combination therapy with mitoxantrone and plasma exchange in aggressive relapsing remitting multiple sclerosis: A preliminary clinical study
por: Tabrizi, Nasim, et al.
Publicado: (2012)

Mycophenolate mofetil in combination with interferon beta-1a in the treatment of relapsing-remitting multiple sclerosis: A preliminary study
por: Etemadifar, Masoud, et al.
Publicado: (2011)

The outbreak fingolimod cardiovascular side effects in relapsing-remitting multiple sclerosis patient: A longitudinal study in an Iranian population
por: Abdar, Morteza, et al.
Publicado: (2016)

Effect of curcumin on gene expression and protein level of methionine sulfoxide reductase A (MSRA), SOD, CAT and GPx in Freund’s adjuvant inflammation-induced male rats
por: Meshkibaf, MH, et al.
Publicado: (2019)

Does COVID-19 increase the long-term relapsing-remitting multiple sclerosis clinical activity? A cohort study
por: Etemadifar, Masoud, et al.
Publicado: (2022)

Association of COVID-19 with Disability Progression and Disease Exacerbation in People with Relapsing-Remitting Multiple Sclerosis: Evidence from a Year-Long Observational Study
por: Sedaghat, Nahad, et al.
Publicado: (2022)

Patient-Reported Outcomes and Satisfaction after Cervical Epidural Steroid Injection for Cervical Radiculopathy
por: Hashemi, Masoud, et al.
Publicado: (2019)

Analysis of Plasma Using Flow Cytometry Reveals Increased Immune Cell-Derived Extracellular Vesicles in Untreated Relapsing-Remitting Multiple Sclerosis
por: Blandford, Stephanie N., et al.
Publicado: (2022)

Barriers to quality of life in patients with multiple sclerosis: a qualitative study
por: Hosseini, Zahra, et al.
Publicado: (2022)

Untreated Human Infections by Trypanosoma brucei gambiense Are Not 100% Fatal
por: Jamonneau, Vincent, et al.
Publicado: (2012)

Clinical effectiveness and safety of fingolimod in relapsing remitting multiple sclerosis in Western Iran
por: Ouspid, Elham, et al.
Publicado: (2018)

The S100B Inhibitor Pentamidine Ameliorates Clinical Score and Neuropathology of Relapsing—Remitting Multiple Sclerosis Mouse Model
por: Di Sante, Gabriele, et al.
Publicado: (2020)

Alternate dosing of fingolimod in relapsing-remitting multiple sclerosis: A systematic review
por: Ghadiri, Fereshteh, et al.
Publicado: (2023)

Antibodies against apoB100 peptide 210 inhibit atherosclerosis in apoE(-/-) mice
por: Dunér, Pontus, et al.
Publicado: (2021)

Uptake of (68)gallium in atherosclerotic plaques in LDLR(-/-)ApoB(100/100 )mice
por: Silvola, Johanna MU, et al.
Publicado: (2011)

Lifestyle and Health Factors Associated with Progressing and Remitting Trajectories of Untreated Lower Urinary Tract Symptoms among Elderly Men
por: Marshall, Lynn M., et al.
Publicado: (2014)

Polymorphisms of serotonin transporter gene and psychological status in patients with multiple sclerosis
por: Farjadian, Shirin, et al.
Publicado: (2018)

Safety and efficacy of fingolimod in Iranian patients with relapsing-remitting multiple sclerosis: An open-label study
por: Doosti, Rozita, et al.
Publicado: (2021)

Relapsing/remitting type 1 diabetes
por: van Megen, Kayleigh M., et al.
Publicado: (2017)

Interaction of nicotine with morphine potency in Paramecium caudatum
por: Shahrokhi, Seyed Sajad, et al.
Publicado: (2019)

VDR and CYP24A1 Expression Analysis in Iranian Relapsing-Remitting Multiple Sclerosis Patients
por: Sadeghi, Hashem, et al.
Publicado: (2017)

Western Diet Decreases Hepatic Drug Metabolism in Male LDLr(−/−)ApoB(100/100) Mice
por: Koponen, Markus, et al.
Publicado: (2023)

Explaining the facilitators of quality of life in patients with multiple sclerosis: a qualitative study
por: Homayuni, Atefeh, et al.
Publicado: (2021)

Balance Changes in Patients With Relapsing-Remitting Multiple Sclerosis: A Pilot Study Comparing the Dynamics of the Relapse and Remitting Phases
por: Findling, Oliver, et al.
Publicado: (2018)

Macrophage Immune Response Suppression by Recombinant Mycobacterium tuberculosis Antigens, the ESAT-6, CFP-10, and ESAT-6/CFP-10 Fusion Proteins
por: Seghatoleslam, Atefeh, et al.
Publicado: (2016)

Optic coherence tomography findings in relapsing-remitting multiple sclerosis patients of the northwest of Iran
por: Talebi, Mahnaz, et al.
Publicado: (2013)

A concise review on the role of MIR100HG in human disorders
por: Ghafouri‐Fard, Soudeh, et al.
Publicado: (2023)

A Case of Relapsing-Remitting Tumefactive Demyelination
por: Wadhwa, Ankur, et al.
Publicado: (2019)

Relapsing and remitting viral diseases of the nervous system
por: Johnson, Richard T.
Publicado: (1984)

Endocarditis following ocrelizumab in relapsing-remitting MS
por: Faissner, Simon, et al.
Publicado: (2020)

Postural Control in Relapsing-Remitting Multiple Sclerosis
por: Cusin, Flavia Salvaterra, et al.
Publicado: (2022)

Investigation of human apoB48 metabolism using a new, integrated non‐steady‐state model of apoB48 and apoB100 kinetics
por: Björnson, E., et al.
Publicado: (2019)

Atheroprotective Vaccination with MHC-II Restricted Peptides from ApoB-100
por: Tse, Kevin, et al.
Publicado: (2013)

Identification of apoB‐100 Peptide‐Specific CD8+ T Cells in Atherosclerosis
por: Dimayuga, Paul C., et al.
Publicado: (2017)

Biphasic Production of Anti-ApoB100 Autoantibodies in Obese Humans and Mice
por: Choe, Moon Kyung, et al.
Publicado: (2021)

Anti-Apo B-100 Autoantibody is a Marker of Unstable Coronary Plaque
por: Imai, Minami, et al.
Publicado: (2021)

Immunization using ApoB-100 peptide–linked nanoparticles reduces atherosclerosis
por: Chyu, Kuang-Yuh, et al.
Publicado: (2022)

A non-randomized clinical trial to evaluate the effect of fingolimod on expanded disability status scale score and number of relapses in relapsing-remitting multiple sclerosis patients
por: Mazdeh, Mehrdokht, et al.
Publicado: (2019)

Novel fatty acyl apoE mimetic peptides have increased potency to reduce plasma cholesterol in mice and macaques
por: Anantharamaiah, G. M., et al.
Publicado: (2018)

Prolyl oligopeptidase is inhibited in relapsing-remitting multiple sclerosis
por: Tenorio-Laranga, Jofre, et al.
Publicado: (2010)

Cannot write session to /tmp/vufind_sessions/sess_a085qshekqo6575rfq5ncp9ihh